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Abstract 
Concentrations of insulin in the brain are several folds higher than blood plasma 
levels. Insulin in the brain regulates the metabolism, molecular composition and 
cognitive performance of microcircuits, reduces food intake and cerebral insulin 
levels are altered in diabetes, aging, obesity and Alzheimer’s disease. Released by 
pancreatic beta cells, insulin passes the blood brain barrier, but sources of locally 
released insulin still remain unclear. We find that insulin is strongly expressed in 
GABAergic neurogliaform cells in the cerebral cortex of the rat detected by single 
cell digital polymerase chain reaction. Focal application of glucose or 
glibenclamide to neurogliaform cells mimics the excitation suppressing effect of 
external insulin on local microcircuits via insulin receptors. Thus, neurogliaform 
cells might link GABAergic and insulinergic action in cortical microcircuits. 
  
Introduction 
Insulin is present in the central nervous system  in concentrations of 10 to 100 times 
higher than plasma levels depending on the area of the brain (Havrankova et al., 1978b). 
Insulin regulates the metabolism, molecular composition and cognitive performance of 
microcircuits (Wan et al., 1997; Beattie et al., 2000) with specific alterations in diabetes, 
aging, obesity and Alzheimer’s disease (Gasparini et al., 2002; Porte et al., 2005). Since 
this first report suggesting the presence of both pancreatic and locally synthesized 
insulin in the brain (Havrankova et al., 1978b), a multitude of studies argued in favor of 
peripheral and central sources. Insulin can cross the blood-brain barrier  as shown by 
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increased insulin levels in the cerebrospinal fluid following infusion of insulin in the 
periphery (Margolis and Altszuler, 1967) and studies finding correlation between 
steady-state endogenous insulin levels in the plasma and cerebrospinal fluid (Woods 
and Porte, 1977) suggesting that insulin enters CNS through the blood-brain barrier by a 
saturable transport system (Banks et al., 1997). However, local insulin synthesis in the 
central nervous system was suggested by variable brain versus blood insulin ratios in 
experimental paradigms and in pathological states (Havrankova et al., 1979; Baskin et 
al., 1985; Gasparini et al., 2002; Pilcher, 2006) and by in situ hybridization and 
immunocytochemical studies detecting insulin mRNA in developing and adult neurons 
and neuronal progenitor cells (Dorn et al., 1983; Devaskar et al., 1994; Kuwabara et al., 
2011, Mehran et al. 2012) but the identity of neurons expressing insulin in terms of 
functional cell classes is not clear. We determined the number of insulin mRNAs in 
various cell classes in the cerebral cortex and tested if insulin can be released in the 
local microcircuit. 
  
Materials and Methods 
Electrophysiology and Imaging. All procedures were performed with the approval of 
the University of Szeged and in accordance with the National Institutes of Health Guide 
to the Care and Use of Laboratory Animals. Male wistar rats (P22-35) were 
anaesthetized by intraperitoneal injection of ketamine (30mg/kg) and xylazine 
(10mg/kg), and following decapitation, coronal slices (350µm) were prepared from the 
somatosensory cortex. Slice preparation and recordings were performed as described 
5 
(Olah et al. 2009). Micropipettes (5-7M) were filled with (in mM) 126 K-gluconate, 4 
KCl, 4 ATP-Mg, 0.3 GTP-Na2, 10 HEPES, 10 creatine phosphate and 8 biocytin (pH 
7.25; 300mOsm); in low extracellular glucose concentrations the intracellular solution 
did not contain ATP-Mg, GTP-Na2 and creatine phosphate. Signals were filtered at 5 
kHz, digitized at 10 kHz and analyzed with PULSE software (HEKA). Voltage clamp 
protocols were applied according to (Zawar et al., 1999). Detection of spontaneous 
EPSCs were performed with NeuroMatic functions for Igor Pro (Wavemetrics). In our 
low chloride recording conditions, reversal potential of unitary inhibitory postsynaptic 
potential was -73.3±3mV thus, separation of GABAergic currents was based on 
polarity. After Gaussian filtering, EPSC events were detected with the threshold 
detection algorithm as described by Kudoh and Taguchi (2002) and events were 
reviewed after automatic detection. Threshold was set to 3pA, onset time limit was set 
to 2ms, which defines the maximum interval from the baseline to the deflection reaches 
the threshold. Peak time limit was set to 3ms. For imaging, neurogliaform cells were 
filled with 10μM Alexa594 and 120μM OGB-1 (Invitrogen) added to the ATP free 
intracellular solution with the application of the hypoglycaemic extracellular solution 
and detection of signals was performed with a Revolution XD system and IQ Software 
(Andor). Data are presented as mean±S.D. throughout, n values refer to the number of 
neurons, statistical test are defined for each paradigm. 
Histology. Visualization of biocytin and correlated light- and electron microscopy was 
performed as described earlier (Olah et al., 2009). Three-dimensional light microscopic 
reconstructions were carried out using Neurolucida (MicroBrightfield) with 100x 
objective. 
6 
Single cell harvesting. At the end of electrophysiological recordings, the intracellular 
content was aspirated into the recording pipette by application of a gentle negative 
pressure while maintaining the tight seal. The pipette was then delicately removed to 
allow outside-out patch formation, and the content of the pipette (2l) was expelled into 
a low-adsorbtion test tube (Axygen). Sample was snap-frozen in liquid nitrogen and 
stored or immediately used for RT. 
First-strand cDNA synthesis. RT was carried out in two steps. First step was done for 
5 min at 65°C in a total reaction volume of 5µl, containing 2µl intracellular solution 
with the cytoplasmic content of the neuron, 0.3µl reverse primer (Bioneer), 0.3µl 10mM 
dNTPs (Life Technologies, Foster City, CA), 1µl 5X first-strand buffer, 0.3µL of 
0.1mol/L DTT, 0.3µl of RNase inhibitor (Life Technologies) and 100U of reverse 
transcriptase (Superscript III; Invitrogen). RT primers were designed using CLC Main 
Workbench (CLC Bio, Aarhus, Denmark) software and the sequences were the 
following: rps18: 5’-ATTAACAGCAAAGGCCCA-3’; ins2: 5’-
TTTATTCATTGCAGAGGGG-3’. Second step of the reaction was carried out at 50°C 
for 1 h and then the reaction was stopped by heating at 70°C for 15 min. The RT 
reaction mix was used in PCR amplification. 
Single cell QRT-PCR. Reactions were carried out after preamplification of cDNA in a 
total volume of 20μl (5µl RT product, 1µl of Taqman® primer (rps18: 
Rn01428913_gH; ins2: Rn01774648_g1), 10µl TaqMan® PreAmp Master Mix (Life 
Technologies) and 4.5µl nuclease-free water) in MyGenie 32 Thermal Block (Bioneer) 
using protocols as described (Faragó et al., 2013).  We repeated QRT-PCRs (traditional 
and digital) amplifying both the control gene rps18 and ins2 without reverse 
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transcriptase reaction and found no amplification and no PCR products meaning that 
possible genomic DNA amplification background under our conditions was negligible. 
To further eliminate the possibility of amplifying genomic DNA, we tried to amplify the 
read through of ins2-igf2 mRNA transcript and also multiple introns of the ins2 as well 
as intergenic region at the ifngr1 gene locus on chromosome 1 and neither of these 
primer sets gave positive results during QRT-PCR. 
Sequencing. We sequenced 4 individual PCR products from 4 individual neurogliaform 
cells using capillary electrophoresis sequencing on 3500 Genetic Analyzer (Life 
Technologies). After purification of the products, we used 4 different sequencing 
primers using the following primer sequences: FOR1: 5’- 5’-cccatgtcccgccgcg-3’ (16) 
FOR2: 5’-gtggaggacccacaagtg-3’ (18) REV1: 5’-tgccaaggtctgaaggtcac-3’ (20) REV2: 
5’-ttctgccgggccacctcc-3’ (18). 
Digital PCR. For digital PCR analysis, in case of rps18 2.5 µl RT mixture or in case of 
ins2 5µl RT reaction mixture, 2µl Taqman® Assays, 10µl OpenArray® Digital PCR 
Master Mix (Life Technologies) and nuclease free water (2-4.5µl) were mixed in a total 
volume of 20µl. The mixture was distributed on an OpenArray® plate, cycled on an 
OpenArray® NT cycler and analysed using the Biotrove OpenArray® Digital PCR 
Software (version 1.0). as described (Faragó et al., 2013).  For our dPCR protocol 
amplification reactions with CT confidence values below 100 as well as reactions having 
CT values below 23 and over 33 were considered primer dimers or background signals, 
respectively, and excluded from the dataset.  
Radioimmunoassay. Insulin extraction of cells was performed in the cold by the acid-
ethanol technique. Radioimmunoassay (Sensitive Rat Insulin RIA kit, Millipore) was 
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used to determine insulin contents with a sensitivity of 2pg/tube. BCA protein assay kit 
(Pierce) was used for detecting total protein content. 
 
Results 
We tested whether different neocortical neuron types, all of them identified by whole 
cell recordings and subsequent light microscopic assessment (Fig.1A), express the 
mRNA of the ins2 gene encoding preproinsulin in the rat (Twigger et al., 2007). After 
electrophysiological and anatomical identification of cell types based on 
characterization of membrane and firing properties (Fig.1A), we harvested the 
cytoplasm of the recorded cells and applied conventional single cell QRT-PCR with 
pre-amplification protocol and detected ins2 mRNA in 15 out of 19 neurogliaform cells 
(Fig.1C). To exclude any possibilities in amplifying DNA fragments other than ins2, we 
sequenced four individual PCR products from n=4 neurogliaform cells and found 100% 
match (84/84; 47/47; 42/42, 31/31) to the ref|NM_019130.2| Rattus norvegicus insulin 2 
(ins2) mRNA sequence. In order to determine the number of ins2 mRNA molecules 
present in the harvested perisomatic cytoplasm of these cell types, we adapted the 
digital PCR method to single neurons without preamplification steps which would have 
decreased reliability (Farago et al., 2013) (Fig.1C). In high extracellular glucose 
concentration (10mM) which is standard for brain slice electrophysiology experiments, 
individual neurogliaform cells (n=10) contained higher numbers of ins2 mRNAs 
(30±13) compared to pyramidal (7±2, n=6) and fast spiking cells (5±3, n=5, p<0.002, 
Kruskal-Wallis test). As a functional control, we lowered the glucose concentration to 
levels close to what was found in the brain during normoglycemia (2.4mM) and 
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hypoglycemia (0.5mM)(Silver and Erecinska, 1994) and this decreased the number of 
ins2 mRNA molecules in single neurogliaform cells to 14±3 (n=5, p<0.008, Kruskal-
Wallis test) and further to 7±4 per cell (n=5, p<0.04). In contrast, copy numbers of 
rps18 mRNAs coding the homeostatic ribosomal protein S18(Twigger et al., 2007) were 
similar in neurogliaform (n=16, 65±18), pyramidal (n=14, 63±26) and fast spiking cells 
(n=15, 61±25) regardless of external glucose concentrations. In further control 
experiments, we determined the number of rps18 (26±6) and ins2 (1±0.8) mRNAs in 
glial cells (n=5 and 4, respectively) showing that our data on mRNA copy numbers 
exclude DNA contamination which might arise in small cells. The copy number of 
rps18 (p<0.01) and ins2 (p<0.04) mRNAs in glial cells was less than in either of the 
three neuron types we tested (Fig. 1C). In addition, we repeated conventional and digital 
PCRs amplifying both rps18 and ins2 without reverse transcriptase reaction and found 
no amplification and no PCR products meaning that genomic DNA amplification was 
negligible (Fig. 1C).  
An increase in extracellular glucose level might act as a physiological trigger in 
releasing insulin from neurogliaform cells containing ins2 mRNAs. In order to test this 
hypothesis, we first searched for electrophysiologically measurable effects of external 
insulin in brain slices and administered insulin in the bath in concentrations (100nM) 
taking into account extra- and intracellular space ratios (0.18) and the ~140m diffusion 
into the slice pushing local concentrations down to a few nanomolar at our recording 
sites  (Havrankova et al., 1978a, Nicholson and Sykova, 1998). Insulin reversibly 
decreased the frequency (from 13.0±9.4Hz to 7.3±5.5Hz, n=16, p<0.001, Wilcoxon-
test, Fig. 2A)  and amplitude (from 12.1±8.13pA to 10.1±6.28pA, n=15, p<0.005) of 
spontaneous EPSCs arriving to neocortical neurons in hypoglycaemia (0.5mM) and 
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application of the specific insulin receptor antagonist S961 (20nM)(Schaffer et al., 
2008) prevented the effect (12.2±8.6Hz and 12.5±9.47pA). To test whether 
neurogliaform cells could mimic the reversible effect of externally added insulin, we 
performed simultaneous paired recordings in hypoglycaemic (0.5mM) conditions and 
puffed hyperglycaemic extracellular solution (10mM) locally to the soma of 
neurogliaform cells while measuring the frequency of spontaneous EPSCs arriving to 
neighbouring neurons (pyramidal cells (n=5), fast spiking basket (n=4) and axo-axonic 
(n=1) cells, data are pooled as no differences were observed between cell types)(Fig. 
2B). Relative to control, the frequency (9.0±8.3Hz) of spontaneous EPSCs decreased 
following hyperglycaemic puffs to neurogliaform cells to 2.4±1.6Hz (n=10, p<0.004, 
Wilcoxon-test). When applying S961 before local hyperglycaemia on neurogliaform 
cells, the frequency of spontaneous EPSCs remained unchanged (8.7±2.9Hz versus 
8.6±2.2Hz, n=7, p>0.47). The effect of glucose puffs to neurogliaform cells was 
dependent on Y kinase signalling (Spicarova and Palecek, 2010) as shown by 
experiments in which lavendustin (5μM) intracellularly applied in neighboring 
pyramidal cells prevented the glucose-induced decrease in sEPSC frequency and 
amplitude (6.67±5.84Hz vs. 7.12±5.76Hz, n=5, p=0.78 and 12.50±4.45 pA vs. 12.92 
±3.16 pA, p=0.44; Fig. 2C). Paired recordings of layer 2/3 pyramidal cells and 
postsynaptic pyramidal cells  (n=5) and fast spiking basket cells (n=4) showed that 
insulin decreased the amplitude of unitary EPSCs from 7.18±5.02 to 4.61±3.72 pA 
(n=9, p<0.004) but the paired pulse ratio remained stationary (0.82±0.34 and 0.84±0.36, 
respectively, p=0.97; Fig. 2D) suggesting a postsynaptic site of action. Thus, local 
hyperglycaemia on neurogliaform cells triggered insulin receptor mediated responses in 
the microcircuit mimicking the effect of external insulin.  
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In a final series of experiments, we addressed mechanisms leading to insulin-like 
effects of neurogliaform cells. Following previous studies showing that the ATP-
sensitive potassium (KATP) channel blocker glibenclamide promotes both insulin 
expression and release (Taniguchi et al., 2006), we confirmed the presence of KATP 
channels in neurogliaform cells using protocols established for cortical interneurons 
(Zawar et al., 1999). Relative to control conditions having a partially suppressed activity 
of KATP channels due hypoglycaema (0.5mM) in the external solution(Taniguchi et al., 
2006), glibenclamide (20μM) in the bath produced a current with current-voltage 
characteristics of KATP channels in neurogliaform cells (n=8) with a reversal potential (-
96.6±2.9mV) close to the potassium equilibrium potential (Fig. 3A). In addition, bath-
applied glibenclamide (20μM) increased intracellular Ca2+ concentration detected by 
changes in OGB-1 fluorescence averaged in 50 s time windows right before and 100-
150 s after application (n=5, 1.6±0.4% F/F0, p<0.01, Wilcoxon-test, Fig. 3B). 
Glibenclamide (20μM) puffs to the soma of neurogliaform cells in hypoglycaemia 
(0.5mM) decreased the frequency of spontaneous EPSCs arriving to simultaneously 
recorded neighbouring pyramidal cells (n=5) and fast spiking basket cells (n=5) (Fig. 
3C, from 11.3±7.3Hz to 6.1±5.3Hz and S961 (20nM) reversed the effect to 9.2±6.2Hz 
(n=11, p<0.001, Wilcoxon-test, Fig. 3C). When applying S961 before glibenclamide, 
the frequency of spontaneous EPSCs remained unchanged (8.5±7.8Hz versus 
9.7±10.0Hz, n=9, p>0.47, Fig. 3C). Moreover, intracellular application of BAPTA 
(4mM) in the neurogliaform cells targeted by glibenclamide also prevented changes in 
the frequency of spontaneous EPSCs (7.2±2.6Hz versus 6.8±2.7Hz, n=9, p>0.30, Fig. 
3C) confirming that the effect of glibenclamide was Ca
2+
 dependent. Neurogliaform 
cells potentially target GABAB receptors(Olah et al., 2009; Fuentealba et al., 2010) but 
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GABAB blockade with CGP35348 (40μM) did not prevent the suppressing effect of 
glibenclamide on spontaneous EPSC frequencies (10.4±2.8Hz versus 8.5±3.4Hz, n=5, 
p<0.01). In line with our single cell digital PCR data showing moderate ins2 RNA 
expression, we detected no effect on spontaneous EPSC frequencies recorded in nearby 
pyramidal cells (n=14) or fast spiking basket cells (n=6) when locally puffing 
glibenclamide to pyramidal cells (n=11, 9.5±4.5Hz versus 9.1±3.8Hz, p=0.76) or fast 
spiking interneurons (n=9, 7.4±2.8Hz versus 7.1±2.7Hz, p=0.65, Fig. 3C) in 
hypoglycaemia (0.5mM). Finally, we added glibenclamide (20μM) to hypoglycaemic 
(0.5mM) external solution of neocortical brain slices for 30 minutes and detected 
increased insulin levels with radioimmunoassay (80.8±17.5 pg/mg protein, n=10) in 
slices at the end of treatment compared to controls without glibenclamide (60.4±21.7 
pg/mg protein, n=10, p<0.04, Mann-Whitney test, Fig. 3D). Since glibenclamide could 
not trigger insulin receptor mediated effects around pyramidal and fast spiking cells, a 
fraction of this insulin, locally synthesized in acute brain slices in response to 
glibenclamide, could be produced by neurogliaform interneurons. Moreover, slices 
incubated in ACSF containing 2.4 or 10mM glucose showed increased insulin content 
relative to hypoglycaemia (75.4±14.1 and 104.2±26.9 pg/mg protein, n=10, p<0.05 and 
p<0.01, respectively) confirming local insulin synthesis. 
Discussion 
According to a textbook method for identifying a neurotransmitter, neurogliaform cells 
mimicked the reversible effect of externally added insulin by releasing a substance we 
identified as insulin based on the same specific receptor antagonist. It remains to be 
established how and when peptides in general are being released from interneurons. 
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Neuropeptide release was shown to depend on dendritic Ca
2+
 entry, but does not 
necessarily require somatic action potentials (Ludwig et al., 2002). Failing to drive 
insulin release with somatic action potentials suggests that local dendritic 
electrogenesis, possibly in response to focal excitatory inputs to neurogliaform dendrites 
might be required. Action potentials in neurogliaform cells did not decrease sEPSCs 
during GABA receptor and NPY receptor blockade on the neighbouring and 
synaptically coupled cells (data not shown). However, local variations in glucose levels 
in physiologically relevant concentrations or targeted glibenclamide application were 
capable of triggering insulin receptor mediated action of neurogliaform cells without 
spikes  as glibenclamide (4.2±1.4 mV, n=5, p<0.02) or glucose (4.4±0.6mV, n=8, 
p<0.04) depolarized the soma of neurogliaform cells, and these functions required Ca
2+
 
entry. This suggests that GABAergic cells can contribute to local insulin release in 
conditions when pancreatic insulin supply temporarily or permanently does not match 
demand, e.g. the actual extracellular glucose availability.  
Insulin regulates the metabolism, molecular composition and cognitive performance of 
microcircuits (Wan et al., 1997; Biessels et al., 1998) and application of external insulin 
into the cerebrospinal fluid was found to decrease food intake (Woods et al., 1979; Porte 
et al., 2005). Cerebral insulin levels are altered in diabetes, aging, obesity and 
Alzheimer’s disease (Havrankova et al., 1979; Baskin et al., 1985; Gasparini et al., 
2002; Porte et al., 2005; Pilcher, 2006, Mehran et al. 2012). A decline in cognitive 
functions was proven in type II diabetic patients (Elias et al., 1997) and intranasal 
application of insulin, which does not alter plasma levels but reaches the cerebrospinal 
fluid (Born et al., 2002) was found to be promising in preventing the progression of 
cognitive impairment (Craft et al., 2012). Thus, potential local sources of insulin might 
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have a modulatory effect on neighboring neural microcircuits in health and disease. 
Damage to cortical insulin producing neurons could partially explain lower cerebral 
levels of the hormone in obesity, ageing and Alzheimer’s disease(Havrankova et al., 
1979; Gasparini et al., 2002) and potentially contribute to the onset of these conditions. 
Insulin receptors are abundant in the cerebral cortex(Havrankova et al., 1978a; Porte et 
al., 2005), but the short half-life might prevent neocortical insulin in reaching relatively 
distant brain areas known to mediate insulin receptor dependent processes in energy 
homeostasis and feeding(Porte et al., 2005). Locally however, neuronal insulin might 
fine tune the passage of glucose through the endothelium of local blood vessels 
expressing insulin sensitive glucose transporters(Magistretti et al., 1999; Porte et al., 
2005). Neurogliaform cells use an action potential dependent form of GABAergic 
volume transmission(Olah et al., 2009) which can interact with insulin in regulating the 
efficacy of synapses(Wan et al., 1997; Beattie et al., 2000). Insulin recruits additional 
GABAA receptors to synaptic (Wan et al. 1997) and possibly extrasynaptic membrane 
compartments of pyramidal neurons shunting excitatory inputs and leading to decreased 
firing and a reduced frequency of sEPSCs.  Neurogliaform cells hyperpolarize the 
membrane potential of cells expressing GABAergic receptors in their neighbourhood 
and the insulin receptor dependent effects of non-spiking neurogliaform cells suggested 
here might complement the spike triggered GABAergic actions.  
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Figure 1. Cell type dependent insulin mRNA expression in the cerebral cortex. (Aa) 
Typical responses of a neurogliaform cell (NGFC), pyramidal cell (PC), fast spiking cell 
(FS) and a glial cell (Glia) to hyperpolarizing and depolarizing current pulses recorded 
before harvesting their cytoplasm. (Ab) Anatomical reconstructions of the cells shown 
in Aa, colors of dendrites correspond to firing patterns in Aa, axons are black. (B) 
Single cell quantitative RT-PCR results of the ins2 gene in neurogliaform cells (top) 
with negative controls (RT-, bottom). (Ca) Representative raw data from a single cell 
digital PCR array showing the rps18 house-keeping gene and ins2 under high (10mM) 
or low (0.5mM; asterisks) extracellular glucose concentrations in neurogliaform cells 
(NGFCs). Results of negative controls for both genes (rps18 - and ins2 -; RT-) are also 
shown. Color coding indicates the cycle number at which reactions crossed threshold 
for detecting ins2 or rps18 in each nanowell. (Cb) The number of ins2 mRNAs in 
neurogliaform cells (green) increased significantly (asterisks) together with the 
extracellular glucose concentration from hypoglycaemic to euglycaemic and further to 
hypergylcaemic extracellular conditions. In contrast, the number of ins2 mRNAs 
remained stable, thus significantly lower in pyramidal (red) and fast spiking (blue) cells 
regardless of changes in glucose concentration. Copy numbers of ins2 in glial cells were 
smaller compared to other cell types tested. 
Figure 2. Neurogliaform cells mimic the action of external insulin via insulin receptors. 
(A) The frequency of spontaneous EPSCs arriving to neocortical neurons was decreased 
in response to physiological concentrations of insulin (100 nM) and the specific insulin 
receptor antagonist S961 (20 nM) reversed the effect. (B) Mimicking the effect of 
insulin shown in (a), local application of hyperglycaemic extracellular solution 
containing 10mM glucose (gluc) to neurogliaform cells (NGFCs) identified 
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electrophysiologically and anatomically decreased the frequency of spontaneous EPSCs 
arriving to neighbouring neurons recorded in hypoglycaemic (0.5mM) conditions and 
S961 (20 nM) also reversed the effect (top, individual experiment, bottom, population 
data). (C) The effect of hyperglycaemic puffs to neurogliaform cells on spontaneous 
EPSCs in neighbouring pyramidal cells was blocked by lavendustin (5μM) 
intracellularly applied in the pyramidal cells. (D) Insulin suppresses the amplitude of 
unitary EPSCs between layer 2/3 pyramidal cells while leaving the paired pulse ratio 
unchanged. 
Figure 3. KATP channels and intracellular Ca
2+
 contribute to insulin receptor mediated 
action of neurogliaform cells. (A) Current-voltage (I-V) relationship of the 
glibenclamide sensitive component of currents recorded in a late spiking (inset) 
neurogliaform cell in response to ramping membrane potential from -145 to -65mV with 
and without glibenclamide (20μM). (B) A neurogliaform cell identified by its firing 
pattern (top) responds to bath applied glibenclamide (20μM) with an increase of the 
intracellular Ca
2+
 concentration detected by changes in OGB-1 fluorescence (right) in 
one of the dendrites (bottom, red border indicates imaged area). (C) Whole cell 
recordings performed in hypoglycemia (0.5mM) show that glibenclamide (20µM) 
delivered to neurogliaform cells (NGFC) significantly decreased the frequency of 
EPSCs in simultaneously monitored neighbouring neurons and this effect was blocked 
by the insulin receptor blocker S961 applied extracellularly and also by intracellular 
application of BAPTA (B) in the neurogliaform cell. In contrast, glibenclamide applied 
to pyramidal cells (PC) and fast spiking cells (FSC) caused no significant changes in the 
frequency of EPSCs in neighbouring neurons. (D) Time course of sEPSC amplitude 
(top) and frequency (bottom) changes in a representative experiment as shown in C, top 
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left panel. (E) Radioimmunoassay measurements in homogenates of neocortical slices 
showed significantly increased insulin levels relative to hypoglycaemia during 
glibenclamide (glib) application and normo- or hyperglycaemia.  
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